Solcitinib
Modify Date: 2024-01-05 15:32:18
Solcitinib structure
|
Common Name | Solcitinib | ||
|---|---|---|---|---|
| CAS Number | 1206163-45-2 | Molecular Weight | 389.45000 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C22H23N5O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of SolcitinibSolcitinib is an orally active, competitive, potent, selective JAK1 inhibitor, with an IC50 of 9.8 nM, and 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively; Solcitinib is used in the research of moderate-to-severe plaque-type psoriasis. |
| Name | Solcitinib |
|---|---|
| Synonym | More Synonyms |
| Description | Solcitinib is an orally active, competitive, potent, selective JAK1 inhibitor, with an IC50 of 9.8 nM, and 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively; Solcitinib is used in the research of moderate-to-severe plaque-type psoriasis. |
|---|---|
| Related Catalog | |
| Target |
JAK1:9.8 nM (IC50) |
| In Vitro | Solcitinib is an orally active, competitive, potent, selective JAK1 inhibitor, with an IC50 of 9.8 nM, and 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively. Solcitinib is used in the research of moderate-to-severe plaque-type psoriasis[1]. |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Molecular Formula | C22H23N5O2 |
| Molecular Weight | 389.45000 |
| Exact Mass | 389.18500 |
| PSA | 79.60000 |
| LogP | 1.51 |
| Index of Refraction | 1.723 |
| Storage condition | 2-8℃ |
| N-(5-{4-[(3,3-Dimethyl-1-azetidinyl)carbonyl]phenyl}[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide |
| UNII-3V7GQ1260K |
| N-(5-{4-[(3,3-dimethylazetidin-1-yl)carbonyl]phenyl}[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide |
| G154578 |
| solcitinibum |
| GSK2586184A |
| GLPG0778 |
| Cyclopropanecarboxamide, N-[5-[4-[(3,3-dimethyl-1-azetidinyl)carbonyl]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]- |
| solcitinib |